CNS Pharmaceuticals (CNSP) Share-based Compensation (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Share-based Compensation came in at $85068.0 in Q4 2025, down 34.51% YoY from $129900.0 in Q4 2024, and up 137.91% on a QoQ basis from $35757.0 in Q3 2025.
CNS Pharmaceuticals (CNSP) Share-based Compensation (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 8 years of Share-based Compensation data on file, last reported at $85068.0 in Q4 2025.
- Quarterly Share-based Compensation fell 34.51% year-over-year to $85068.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $480268.0 (up 416.81% YoY) and the FY2025 annual result came in at $187728.0, down 77.62% from the prior year.
- Share-based Compensation grew to $85068.0 in Q4 2025, from $35757.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $506647.0 in Q3 2021 to a low of -$774742.0 in Q4 2023.
- A 5-year average of $188435.0 and a median of $286841.0 in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation tumbled 367.41% — and 2024, when it surged 232.67%.
- Tracing CNSP's Share-based Compensation over 5 years: stood at $316906.0 in 2021, then decreased by 8.58% to $289719.0 in 2022, then tumbled by 367.41% to -$774742.0 in 2023, then surged by 116.77% to $129900.0 in 2024, then tumbled by 34.51% to $85068.0 in 2025.
- The last three Share-based Compensation figures came in at $85068.0 (Q4 2025), $35757.0 (Q3 2025), and $62367.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CNS Pharmaceuticals | 2.64 Mn | -4.56 Mn | - | 85,068.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 85,068.00 |
| Dec 31, 2025 | 85,068.00 |
| Sep 30, 2025 | 35,757.00 |
| Sep 30, 2025 | 35,757.00 |
| Mar 31, 2025 | 62,367.00 |
| Mar 31, 2025 | 62,367.00 |
| Dec 31, 2024 | 129,900.00 |
| Dec 31, 2024 | 129,900.00 |
| Sep 30, 2024 | 85,699.00 |
| Sep 30, 2024 | 85,699.00 |
| Jun 30, 2024 | 366,400.00 |
| Jun 30, 2024 | 366,400.00 |
| Mar 31, 2024 | 202,933.00 |
| Mar 31, 2024 | 202,933.00 |
| Dec 31, 2023 | -774,742.00 |
| Dec 31, 2023 | -774,742.00 |
| Sep 30, 2023 | 59,624.00 |
| Sep 30, 2023 | 59,624.00 |
| Jun 30, 2023 | 110,138.00 |
| Jun 30, 2023 | 110,138.00 |